ストックスクリーナーアプリを入手
5.19
9.96%
0.47
アフターアワーズ：
5.16
-0.03
-0.58%
Bausch Health Companies Inc (BHC) 最新ニュース
Bausch Health is successfully battling generics, Raymond James says - Cantech Letter
Toronto Stock Exchange Rallies With Metals And Health Care Leaders - Finimize
Bausch Health Says Carl Icahn Has 34% Economic Interest In Its Outstanding Shares - MSN
Bausch Health says Carl Icahn has exposure to about 34% of company's shares - MSN
Toronto Stock Exchange Bounces Back With Mining And Health Gains - Finimize
Toronto Stocks Rally; Bausch Health Rises on Expanded Carl Icahn Stake - marketscreener.com
Bausch Health Says Carl Icahn Has 34% Economic Interest In Its Outstanding Shares By Stocktwits - Investing.com India
TSX rises but Trump's Fed comments keep investors cautious - marketscreener.com
Billionaire Carl Icahn builds 34% economic interest in Bausch Health - Reuters
Bausch Health Says Billionaire Carl Icahn Exposed to 34% of Company's Shares - marketscreener.com
Bausch Health Learns Icahn Has 34% Economic Interest in Shares - MSN
Icahn Raises Stake In Bausch Health Significantly - Finimize
Market movers: Stocks that saw action on Tuesdayand why - The Globe and Mail
Bausch Jumps 14% After Icahn Increases Economic Interest to 34% - marketscreener.com
Bausch Health jumps after Carl Icahn’s 34% stake - MSN
Bausch Health says Carl Icahn has economic interest in about 34% of its shares - marketscreener.com
Bausch Health stock jumps after Carl Icahn stake (BHC:NYSE) - Seeking Alpha
Bausch Health updates proxy statement on Icahn’s interest - Investing.com
Bausch Health Addresses Icahn’s Equity Swaps and Adopts Shareholder Rights Plan - TipRanks
Bausch Health shares surge on Icahn’s significant economic interest - Investing.com
Bausch Health Brief: Filing Supplement In Response to Co Learning that Carl Icahn and Affiliates Have Cash-Settled Equity Swaps for Approximately 90 Million of Its Common Shares - marketscreener.com
Bausch Health Announces Filing of Supplement to Proxy Statement - standard-journal.com
Press Release Distribution & PR Platform - ACCESS Newswire
Carl Icahn's Secret 34% Bausch Health Stake Triggers Defensive Poison Pill Response - Stock Titan
April 2025's Top Growth Stocks With Strong Insider Ownership - simplywall.st
13 Best Canadian Penny Stocks to Invest in Now - Insider Monkey
BofA Cuts Price Target on Bausch Health to $5 From $7 - marketscreener.com
TSX falls as Trump's Fed criticism shakes markets - marketscreener.com
Bausch (BHC) Moves 13.3% Higher: Will This Strength Last? - Nasdaq
Analysts Expect Bausch Health Companies Inc. (NYSE:BHC) To Breakeven Soon - simplywall.st
Is Bausch Health Companies (BHC) the Ridiculously Cheap Stock to Invest in? - Yahoo Finance
11 Ridiculously Cheap Stocks to Invest in - Insider Monkey
Bausch Health Provides Update on Solta Medical - marketscreener.com
U.S. District Court Rules in Favor of Bausch Health and FDA in XIFAXAN Case - TipRanks
Bausch Health shares jump on favorable court ruling By Investing.com - Investing.com South Africa
Bausch Health shares jump on favorable court ruling - Investing.com
Bausch says court grants summary judgment in favor of FDA, Salix, and Teva - TipRanks
Major Legal Win: How Bausch Health's Court Victory Protects Billion-Dollar XIFAXAN Franchise Until 2028 - Stock Titan
Fitch raises Bausch Health rating to CCC+ amid refinancing By Investing.com - Investing.com Canada
Fitch raises Bausch Health rating to CCC+ amid refinancing - Investing.com
Fitch Upgrades Bausch + Lomb, Bausch Health But Keeps Both Junk - Bloomberg
Topical Drug Delivery Market Set to Witness Significant Growth - openPR.com
Verteporfin Market Generated Opportunities, Future Scope - openPR.com
Bausch Health Companies IncAdopts Shareholder Rights PlanSEC Filing - marketscreener.com
Scar Treatment Market Set to Witness Significant Growth - openPR.com
Bausch Health Adopts Shareholder Rights Plan to Ensure Fair Treatment - TipRanks
Bausch Health Announces Adoption of Shareholder Rights Plan - The Joplin Globe
Bausch Health's New Poison Pill Defense: Key Details of Shareholder Protection Strategy - Stock Titan
The most oversold and overbought stocks on the TSX - The Globe and Mail
Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin - marketscreener.com
Intraocular Lens Market Overall Study Report 2025-2032 | Bausch - openPR.com
Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program - ACCESS Newswire
New $10K Scholarship Program Empowers Students Affected by Skin Conditions - Stock Titan
Bausch Health secures intent for acne treatment coverage By Investing.com - Investing.com South Africa
Atopic Dermatitis Pipeline 2025: Therapies Under - openPR.com
Bausch Health signs LOI with pan-Canadian Pharmaceutical Alliance for CABTREO - TipRanks
Bausch Health Canada signs Cabtreo public drug plan coverage letter of intent - TipRanks
Bausch Health secures intent for acne treatment coverage - Investing.com Australia
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris - Yahoo Finance
Bausch Health Companies Unit Entered Into A New Senior Secured Credit Agreement - MarketScreener
First-Ever Triple-Action Acne Treatment Now Covered by Canadian Public Drug Plans - Stock Titan
4.83%
1.04%
大文字化:
|
ボリューム (24 時間):